Microvessel density and heparanase over-expression in clear cell renal cell cancer: Correlations and prognostic significances

World Journal of Surgical Oncology

Volumn 9, Issue , 2011, Pages

  Ren, Juchao ^a,b   Liu, Hainan ^a   Yan, Lei ^a   Tian, Sujian ^a   Li, Dawei ^a   Xu, Zhonghua ^a  

^a SHANDONG UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Clear cell renal cell carcinoma; Heparanase; Microvessel density; Prognosis

Indexed keywords

HEPARANASE; BETA GLUCURONIDASE; MESSENGER RNA;

ADULT; ANGIOGENESIS; ARTICLE; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLEAR CELL RENAL CELL CANCER; DISEASE SEVERITY; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; KIDNEY PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; PREVALENCE; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ENZYME IMMUNOASSAY; ENZYMOLOGY; GENETICS; KIDNEY CARCINOMA; KIDNEY TUMOR; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; VASCULARIZATION;

CARCINOMA, RENAL CELL; FEMALE; GLUCURONIDASE; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY NEOPLASMS; LYMPHATIC METASTASIS; MALE; MICROVESSELS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE;

EID: 82455162804     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-9-158     Document Type: Article

References (42)

1. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs 2004, Lyon: IARCPress.
2. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005, 353:2477-2490.
3. Czekierdowski A, Czekierdowska S, Czuba B, Cnota W, Sodowski K, Kotarski J, Zwirska- Korczala K. Microvessel density assessment in benign and malignant endometrial changes. J Physiol Pharmacol 2008, 59(Suppl 4):45-51.
4. Thelen A, Scholz A, Benckert C, Schroder M, Weichert W, Wiedenmann B, Neuhaus P, Jonas S. Microvessel density correlates with lymph node metastases and prognosis in hilar cholangiocarcinoma. J Gastroenterol 2008, 43:959-966.
5. Svagzdys S, Lesauskaite V, Pavalkis D, Nedzelskiene I, Pranys D, Tamelis A. Microvessel density as new prognostic marker after radiotherapy in rectal cancer. BMC Cancer 2009, 9:95.
6. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 2001, 108:341-347.
7. Yurchenco PD, Schittny JC. Molecular architecture of basement membranes. FASEB J 1990, 4:1577-1590.
8. Ferro V, Hammond E, Fairweather JK. The development of inhibitors of heparanase, a key enzyme involved in tumour metastasis, angiogenesis and inflammation. Mini Rev Med Chem 2004, 4:693-702.
9. Tang W, Nakamura Y, Tsujimoto M, Sato M, Wang X, Kurozumi K, Nakahara M, Nakao K, Nakamura M, Mori I, Kakudo K. Heparanase: a key enzyme in invasion and metastasis of gastric carcinoma. Mod Pathol 2002, 15:593-598.
10. Koliopanos A, Friess H, Kleeff J, Shi X, Liao Q, Pecker I, Vlodavsky I, Zimmermann A, Buchler MW. Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res 2001, 61:4655-4659.
11. Shinyo Y, Kodama J, Hongo A, Yoshinouchi M, Hiramatsu Y. Heparanase expression is an independent prognostic factor in patients with invasive cervical cancer. Ann Oncol 2003, 14:1505-1510.
12. Friedmann Y, Vlodavsky I, Aingorn H, Aviv A, Peretz T, Pecker I, Pappo O. Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. Am J Pathol 2000, 157:1167-1175.
13. Gohji K, Hirano H, Okamoto M, Kitazawa S, Toyoshima M, Dong J, Katsuoka Y, Nakajima M. Expression of three extracellular matrix degradative enzymes in bladder cancer. Int J Cancer 2001, 95:295-301.
14. Lerner I, Baraz L, Pikarsky E, Meirovitz A, Edovitsky E, Peretz T, Vlodavsky I, Elkin M. Function of heparanase in prostate tumorigenesis: potential for therapy. Clin Cancer Res 2008, 14:668-676.
15. Hermanek P, Seib H, Wittekind C. Clinical significance and current status. Pathologe 1997, 18:153-159.
16. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982, 6:655-663.
17. Zetser A, Levy-Adam F, Kaplan V, Gingis-Velitski S, Bashenko Y, Schubert S, Flugelman MY, Vlodavsky I, Ilan N. Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci 2004, 117:2249-2258.
18. Doweck I, Kaplan-Cohen V, Naroditsky I, Sabo E, Ilan N, Vlodavsky I. Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival. Neoplasia 2006, 8:1055-1061.
19. Zubac DP, Bostad L, Kihl B, Seidal T, Wentzel-Larsen T, Haukaas SA. The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival. J Urol 2009, 182:2144-2149.
20. Bai RJ, Cheng XG, Qu H, Shen BZ, Han MJ, Wu ZH. Solitary pulmonary nodules: comparison of multi-slice computed tomography perfusion study with vascular endothelial growth factor and microvessel density. Chin Med J (Engl) 2009, 122:541-547.
21. Ben-Izhak O, Kaplan-Cohen V, Ilan N, Gan S, Vlodavsky I, Nagler R. Heparanase expression in malignant salivary gland tumors inversely correlates with long-term survival. Neoplasia 2006, 8:879-884.
22. Vlodavsky I, Ilan N, Naggi A, Casu B. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des 2007, 13:2057-2073.
23. Cohen-Kaplan V, Doweck I, Naroditsky I, Vlodavsky I, Ilan N. Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression. Cancer Res 2008, 68:10077-10085.
24. Nasser NJ. Heparanase involvement in physiology and disease. Cell Mol Life Sci 2008, 65:1706-1715.
25. Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 2006, 38:2018-2039.
26. Goldshmidt O, Zcharia E, Cohen M, Aingorn H, Cohen I, Nadav L, Katz BZ, Geiger B, Vlodavsky I. Heparanase mediates cell adhesion independent of its enzymatic activity. FASEB J 2003, 17:1015-1025.
27. Kuniyasu H, Chihara Y, Kubozoe T, Takahashi T. Co-expression of CD44v3 and heparanase is correlated with metastasis of human colon cancer. Int J Mol Med 2002, 10:333-337.
28. Zetser A, Bashenko Y, Edovitsky E, Levy-Adam F, Vlodavsky I, Ilan N. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res 2006, 66:1455-1463.
29. Gingis-Velitski S, Zetser A, Kaplan V, Ben-Zaken O, Cohen E, Levy-Adam F, Bashenko Y, Flugelman MY, Vlodavsky I, Ilan N. Heparanase uptake is mediated by cell membrane heparan sulfate proteoglycans. J Biol Chem 2004, 279:44084-44092.
30. Gavard J, Patel V, Gutkind JS. Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Dev Cell 2008, 14:25-36.
31. Yang Y, Macleod V, Miao HQ, Theus A, Zhan F, Shaughnessy JD, Sawyer J, Li JP, Zcharia E, Vlodavsky I, Sanderson RD. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem 2007, 282:13326-13333.
32. Vaday GG, Lider O. Extracellular matrix moieties, cytokines, and enzymes: dynamic effects on immune cell behavior and inflammation. J Leukoc Biol 2000, 67:149-159.
33. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 1999, 103:1237-1241.
34. Vlodavsky I, Miao HQ, Medalion B, Danagher P, Ron D. Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor. Cancer Metastasis Rev 1996, 15:177-186.
35. Jiang LJ, Shao CK, He D, Li WG, Wu XZ, Cai DZ. Correlations of extrocellular matrix metalloproteinase inducer and microvessel density to invasiveness of ameloblastoma. Chinese J Cancer 2008, 27:1263-1266.
36. Mikami S, Oya M, Shimoda M, Mizuno R, Ishida M, Kosaka T, Mukai M, Nakajima M, Okada Y. Expression of heparanase in renal cell carcinomas: implications for tumor invasion and prognosis. Clin Cancer Res 2008, 14:6055-6061.
37. Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res 2003, 9:4641-4652.
38. Elmore JM, Kadesky KT, Koeneman KS, Sagalowsky AI. Reassessment of the 1997 TNM classification system for renal cell carcinoma. Cancer 2003, 98:2329-2334.
39. Sandlund J, Hedberg Y, Bergh A, Grankvist K, Ljungberg B, Rasmuson T. Evaluation of CD31 (PECAM-1) expression using tissue microarray in patients with renal cell carcinoma. Tumour Biol 2007, 28:158-164.
40. Fairweather JK, Hammond E, Johnstone KD, Ferro V. Synthesis and heparanase inhibitory activity of sulfated mannooligosaccharides related to the antiangiogenic agent PI-88. Bioorg Med Chem 2008, 16:699-709.
41. Lewis KD, Robinson WA, Millward MJ, Powell A, Price TJ, Thomson DB, Walpole ET, Haydon AM, Creese BR, Roberts KL, Zalcberg JR, Gonzalez R. A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest New Drugs 2008, 26:89-94.
42. Basche M, Gustafson DL, Holden SN, O'Bryant CL, Gore L, Witta S, Schultz MK, Morrow M, Levin A, Creese BR, Kangas M, Roberts K, Nguyen T, Davis K, Addison RS, Moore JC, Eckhardt SG. A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res 2006, 12:5471-5480.